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Objective: To identify serum biomarkers of papillary thyroid cancer.
Methods: Prospective analysis was performed of banked tumor and serum specimens from 99 patients with
thyroid masses. Enzyme-linked immunosorbent assay (ELISA) was employed to measure levels of five serum
proteins previously demonstrated to be up-regulated in papillary thyroid cancer (PTC): angiopoietin-1 (Ang-1),
cytokeratin 19 (CK-19), tissue inhibitor of metalloproteinase-1 (TIMP-1), chitinase 3 like-1 (YKL-40), and galectin-3
(GAL-3). Serum levels were compared between patients with PTC and those with benign tumors.
Results: A total of 99 patients were enrolled in the study (27 men, 72 women), with a median age of 54 years.
Forty-three patients had PTC and 58 cases were benign tumors. There were no statistically significant differences
when comparing all five different biomarkers between PTC and other benign thyroid tumors. The p-values were
0.94, 0.48, 0.72, 0.48, and 0.90 for YKL-40, Gal-3, CK19, TIMP-1, and Ang-1, respectively.
Conclusion: Serum levels of four of the five proteins were elevated in patients with thyroid masses relative to
normal values. However, the difference between benign and PTC was not significant. Two of the markers (Gal-3 &
TIMP-1) displayed a greater potential difference, which may warrant further investigation. This study suggests that
other serum markers should be sought. This is the first study to investigate potential serum biomarkers based on
over-expressed proteins in thyroid cancer versus benign pathology.
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Papillary thyroid cancer (PTC) is one of the few cancers
whose incidence is on the rise. It is considered the most
rapidly increasing of all cancers in Canada [1]. Incidence
has increased by 6.8% per year in males and 8.8% per year
in females since 1998 in Canada with similar results noted
in Europe and the United States [1]. Risk factors for thyroid
cancers include prior radiation, family history and genetics.
Treatment by surgery and radio-iodine therapy is highly
effective; however, due to the difficulty in accurate diagnosis
of thyroid cancer, surgery is often performed on benign
nodules. Benign thyroid masses such goiter, follicular
adenomas and cysts are approximately ten times more
common than thyroid cancers [2]. Pre-operative diagnostic* Correspondence: drrobhart@hotmail.com
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reproduction in any medium, provided the ortests such as U/S, CT scan, and fine needle aspirate (FNA)
often do not provide a definitive diagnosis. In these indeter-
minate cases, diagnostic hemithyroidectomy surgery is
often performed and up to 75% of these patients have
benign disease [3].
Research into the use of genomic techniques for
improved diagnosis has focused on transcript profiling of
well-differentiated thyroid cancer [4]. Genes that appear
to be up-regulated in these studies are numerous. Jazab
et al. demonstrated in a group of 16 patients with PTC
increased gene expression for lectin, galactoside-binding,
soluble, 3 (LGALS3) which codes for galectin-3 (Gal-3)
protein, tissue inhibitor of metalloproteinases 1 (TIMP1),
and chitinase 3-like 1 (CHI3L1) which is also known as
YKL-40 [5]. Baris et al. noted high expression of adenosine
deaminase (ADA), eukaryotic translation initiation factor
2 subunit 2 (EIF2S2), TIMP1, cyclin D1 (CCND1),
cadherin-3 (CDH3) and collagen, type VIII, alpha 1
(COL8A1) in PTC [6]. Niedźwiecki et al. explored the role
of angiopoietin 1 and 2 in thyroid cancers, showing atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients characteristics
Age Sex
Min Max Mean Median Male Female Total
PTC 19 78 52.9 54 17 25 42
Benign 30 81 53.7 54 10 47 57
All 19 81 53.4 54 27 72 99
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of malignancy [7]. Based on a review of these and other
published studies using gene expression analysis, we con-
cluded that YKL-40, Gal-3, cytokeratin 19 (CK19), TIMP-1
and Ang-1 were consistently found to be upregulated.
An alternative approach to tumor transcript profiling is
protein profiling of serum. The main advantages of this ap-
proach are that it is minimally invasive, relatively safe and
can be performed repeatedly. This could provide the basis
for a useful test for screening, diagnosis, treatment and
followup. However, the high complexity of serum makes
identification of biomarkers challenging. Relative to healthy
controls, the levels of serum vascular endothelial growth
factor (VEGF) and matrix metallopeptidase 9 (MMP-9) are
elevated in late-stage PTC; however, as the levels of these
markers do not differentiate between goiter and early stage
PTC, they are not useful for improving diagnosis [8]. Levels
of biotinidase, clusterin, cysteine-rich, angiogenic inducer,
61 (CYR61), enolase 1, nucleolin and prothymosin alpha
(PTMA) have been compared between PTC patients and
healthy controls but no comparison was made with patients
with benign nodules [9]. In spite of these advances, there
are currently no validated serum markers for the diagnosis
of PTC or for risk stratification of thyroid masses.
Our objective was to identify potential serum markers
in subjects with PTC. We hypothesized that markers
that have been shown to be highly expressed in PTC
tumor tissue, especially those that are secreted or present
at the cell surface, would also be elevated in serum, and




This was a prospective study. All patients provided informed
consent and the study was approved by the local Hospital
Ethics Committee. All patients ≥ 18 years old and undergo-
ing hemi-thyroidectomy or total thyroidectomy from July
2009 to June 2011 were enrolled initially in the study.
Patients with human immunodeficiency virus or viral hepa-
titis were not included in the study for investigator handling
safety reasons. After post-operative pathological evaluation,
all patients with thyroid cancer other than PTC were
excluded. Patients were then divided into two main groups
based on their diagnosis: 1) PTC group and 2) control
group. The control group included all patients with benign
thyroid pathology. All specimens were then bar-coded and
patient identifiers removed in order to protect their ano-
nymity and also to blind the operators conducting the
ELISA analysis.
Specimen collections (serum & tissue)
In the operating room prior to induction of general
anesthesia, 2 red top vials of blood were drawn from allpatients. The tubes were left at room temperature for
20-30 minutes to clot and then centrifuged at 3000 rpm
for 10 minutes. If serum separation from erythrocytes
was incomplete, the centrifugation step was repeated.
The serum was aliquoted into 5-8 300 μl microcentri-
fuge tubes in order to limit the number of freeze-thaw
cycles to one. At the same time, immediately upon com-
pletion of the procedure, the thyroid specimen was
processed by a single study pathologist (M.B.). A rep-
resentative portion of the mass was also preserved in
ribonucleic acid stabilizing reagent (RNAlater, Ambion)
for future analysis. Both serum and tissue specimens were
subsequently stored in a freezer at -80°C.
Enzyme-linked immunosorbent assay
All the collected serum specimens were analyzed by
ELISA according to the manufacturers’ instructions.
ELISA kits for Ang-1 (catalog number DANG10), TIMP-1
(catalog number DTM100) and Gal-3 (catalog number
DGAL30) were from the Research and Diagnostics (R&D)
Systems, Inc., Minneapolis, MN, USA. The kit for YKL-40
(catalog number Microvue YKL-40 8020 (QI)) was made
by Quidel Corp., San Diego, CA, USA. The CK19 ELISA
kit (catalog number CSB-E09180H) was from CUSABIO,
(www.cusabio.com). All ELISA washing steps were
performed using a BioTek Elx50 microplate strip washer
programmed as required. All readings were made on a
Spectramax 384 Plus plate reader (Molecular Devices,
Sunnyvale, CA, USA) using the SoftMax Pro software
package. All samples, standards and blanks were analyzed
in duplicate.
Statistical analysis
P values for the comparison of the means of the PTC and
control groups for each of the 5 serum proteins were
determined using t-tests. Random forest classification was
performed using the R package random Forest. The ran-
dom forest analysis was carried out with parameters ntree,
mtry and nodesize set to 50 000, 3 and 1 respectively. Nor-
mal values for each of the 5 serum proteins were taken
from references as indicated [10,11,12,13,14].
Results
A total of 99 patients were enrolled in the study (42
PTC & 57 benign). The patients’ characteristics are
Table 2 PTC patients’ and tumor characteristics
# Sex Age Dx* Procedure Level 6










(yes = 1, no = 0)
ETE*
(yes = 1, no = 0)
Multicentricity
(yes = 1, no = 0)
Number
of foci
1 M 42 MP* Hemi *(Lt) 1 0/3 0 _ 0.1 0 0 0 1
2 F 53 PTC* Total Thyroid* 1 1/12 0 _ 0.7 0 1 0 1
3 F 38 MP Hemi (Rt) 0 0 0 _ 0.3 0 0 1 2
4 F 69 PTC Hemi (Lt) 1 6/16 1 4/98 0.2 0 0 1 3
5 M 59 MP Total Thyroid 1 0/17 0 _ 0.2 0 0 0 1
6 M 55 PTC Total Thyroid 1 0/7 0 _ 0.3 0 0 1 5
7 F 35 PTC Total Thyroid 1 0/18 0 _ 5.5 0 0 1 7
8 F 42 MP Hemi (Rt) 0 0 0 _ 0.2 0 0 1 2
9 F 36 PTC Hemi (Rt) 0 0 0 _ 3 0 0 1 6
10 M 46 PTC Hemi (Lt) 0 0 0 _ 6.5 1 0 1 2
11 F 19 PTC Total Thyroid 1 3/4 1 10/37 7 1 1 1 +*
12 M 63 PTC Total Thyroid 1 0/7 0 - 1 0 0 0 1
13 M 57 PTC Total Thyroid 1 4/13 0 - 2 1 1 0 1
14 M 67 PTC Total Thyroid 1 0/2 0 _ 1.3 0 0 1 4
15 M 40 PTC Total Thyroid 1 11/15 1 13/44 0.5 1 0 1 10
16 M 66 MP Hemi (Lt) 1 0/1 0 _ 2.5 0 0 0 1
17 F 53 PTC Total Thyroid 1 0/5 0 _ 4 0 0 1 2
18 M 77 PTC Total Thyroid 0 0 0 _ 0.3 0 0 1 3
19 F 56 PTC Hemi (Lt) 0 0 0 _ 1.7 0 0 0 1
20 F 47 PTC Hemi (Rt) 0 0 0 _ 1.1 0 0 1 3
21 F 58 PTC Total Thyroid 1 0/6 0 _ 1.6 0 0 1 2
22 F 56 PTC Total Thyroid 1 0/20 0 _ 2 1 1 1 2
23 M 53 PTC Total Thyroid 1 7/18 1 11/46 1.8 0 1 1 +
24 F 75 PTC Total Thyroid 1 0/13 0 _ 0.5 0 0 1 2
25 F 35 PTC Hemi (Lt) 0 0 0 _ 1.3 0 0 1 3
26 F 41 PTC Total Thyroid 1 3/12 0 _ 1.7 0 0 1 10
27 F 62 PTC Total Thyroid 1 0/13 0 _ 2.2 0 0 0 1
28 M 42 PTC Total Thyroid 1 4/6 0 _ 1.7 1 1 0 1
29 F 72 PTC Hemi (Rt) 0 0 0 _ 1.5 0 0 0 1
30 M 37 PTC Total Thyroid 1 0/11 0 _ 4.5 0 0 0 1
31 M 72 PTC Total Thyroid 1 7/9 1 9/18 2.5 1 1 1 +























Table 2 PTC patients’ and tumor characteristics (Continued)
33 F 40 PTC Total Thyroid 1 0/6 0 _ 0.9 0 0 1 4
34 F 40 PTC Total Thyroid 1 7/8 0 _ 4 1 0 1 2
35 F 35 PTC Total Thyroid 1 1/13 1.o 0 0 1
36 M 78 PTC Hemi (Rt) 0 0 0 _ 8 0 0 0 1
37 F 61 MP Hemi (Rt) 0 0 0 _ <0.1 0 0 0 1
38 M 77 MP Total Thyroid 0 0 0 _ 0.4 0 0 0 1
39 F 70 MP Hemi (Rt) 0 0 0 _ 0.2 0 0 1 2
40 M 56 PTC Total Thyroid 1 2/3 1 0 2.5 1 1 0 1
41 F 49 MP Hemi (Lt) 0 0 0 _ 0.1 0 0 0 1
42 F 56 MP Hemi (Rt) 0 0 0 _ 0.1 0 0 0 1
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serum markers were measured by ELISA and the levels
were compared between PTC patients and the control
group, consisting of all benign thyroid conditions. As
can be seen in Table 3 & Figure 1, no significant differ-
ences were detected for any of the proteins measured.
Therefore, the serum levels of these proteins are not diag-
nostic using univariate statistical analysis. The serum
levels of these markers were also plotted using violin plots
(Figure 2). In these plots the width of the image is propor-
tional to the number of patients at each serum value. This
can aid in the identification of smaller subsets of patients
with elevated levels in cases where the mean is dominated
by the bulk of the patient values. However, again in this
case, no significant sub-groups are apparent.
The potential markers were also analyzed using multi-
variate statistical analysis. Specifically, the data were
analyzed using random forest analysis using R [15]. In this
technique, approximately two thirds of the samples were
chosen at random to generate a classification tree. At each
tree node a random subset of variables (mtry) was selected
with the variable responsible for the largest split used to
split the node. This process was iterated ntree number of
times to create an ensemble of classification trees in which
sample prediction is accomplished through a majority vote.
As in the case of the univariate analysis, the multivariate
analysis using random forest did not reveal any serum
markers that were significant for diagnosis. In Figure 3, the
box plot shows that the margin, which is a measure of the
ability to distinguish the two groups using the serum
marker levels, is close to zero. This indicates poor predic-
tive ability. Similarly, the plot on the right of Figure 3 shows
little separation for the PTC and reference groups.Discussion
Up to this date the gold standard for the diagnosis of
thyroid cancer remains pathological evaluation of surgi-
cally obtained thyroid tissue. Since the introduction of
FNA in the 1970s the preoperative diagnostic accuracy
of thyroid nodules has greatly improved [16]. However,
FNA still has significant limitation in the diagnosis of
thyroid nodules with an overall sensitivity and specificity
from 65-98% and 72-100%, respectively [17]. Microarray
technology has significantly improved the understandingTable 3 Tumor marker serum measurement values
YKL-40 Gal-3
PTC 129 ± 77 7.07 ± 2.79
Reference 129 ± 99 6.6 ± 3.0
P-value 0.995 0.488
Normala 43 ± 25 [10] 2.2 [11]
* All concentrations in ng/ml, a Values taken from references as indicated.of cancer pathophysiology as well by providing valuable
clinical information. This has yielded multiple genes that
have been demonstrated to be up-regulated in PTC.
Certain genes encode secretory proteins that with the
use of commercially available ELISA kits are measurable
in serum. In 2001, Huang et al. published the first study
describing genes that are up-regulated in PTC based on
microarray [18]. Comparing 8 pairs of normal and PTC
thyroid tissue resulted in the detection of 24 genes that
were up-regulated in PTC [18]. In the present study we
measured serum levels of YKL-40, Gal-3, CK19, TIMP-1
and Ang-1 proteins using a commercially available
ELISA kit.
Tissue inhibitor of metalloproteinase-1 (TIMP-1)
As its name suggests, TIMP-1 inhibits a variety of metal-
loproteinases. Its expression is dependent on BRAF and
NF-κB using in vitro models, where it also influences proli-
feration [19]. High expression of TIMP-1 is indicative of an
invasive phenotype. In 2000, Maeta et al. investigated the
expression of both the TIMPs and matrix metalloprotei-
nases (MMPs) in PTC, which were up-regulated relative to
normal tissue [20]. Similar results were also obtained by
others and confirmed at the protein level [21-25]. Serum
levels in thyroid cancer patients have not been previously
measured; however, levels in pancreatic cancer patients
and, to a lower extent in chronic pancreatitis, have been
shown to have diagnostic potential [26]. In metastatic
breast cancer patients, elevated serum TIMP-1 levels were
shown to correlate with poor response to therapy and lower
overall survival [27]. In our study the TIMP-1 levels in PTC
and control samples were 162 ng/ml and 154 ng/ml, re-
spectively. The serum level did not show any significant dif-
ference despite the strong evidence in the literature for
elevated gene and protein expression of TIMP-1. This is
the first study to demonstrate equivalent levels of serum
TIMP-1 in patients with PTC and benign thyroid nodules.
Chitinase 3-like 1 (YKL-40)
Chitiniase 3-like 1 has been found to be up-regulated in
PTC [18] and in numerous other cancers where it appears
to promote angiogenesis [28]. The serum levels of this pro-
tein, which is also known as YKL-40, have not been studied
in PTC patients. However, it has been found to be elevatedCK-19 Ang-1 TIMP-1
8.1 ± 6.1 21 ± 11 162 ± 60
8.6 ± 5.4 21 ± 12 154 ± 42
0.730 0.483 0.910
1.4 +0.3 [12] 58 ± 5 [13] 95 + 26 [14]
Figure 1 Boxplot of serum marker levels in the PTC and reference group, which consists of all benign conditions. Boxes contain 25th
and 75th percentile.
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cancers although it is also elevated in various inflammatory
conditions [29]. The mean concentration of YKL-40 in both
PTC and control samples was 129 ng/mL, which is higher
than the level reported in healthy controls (43 ng/ml) [10].Lectin, galactoside-binding, soluble, 3 (LGALS3),
galectin – 3 (Gal-3)
Galectins are a family of carbohydrate-binding proteins with
a high affinity for β-galactoside. Gal-3 is implicated in cell
growth and differentiation, cell adhesion, angiogenesis,
Figure 2 Violin plot of serum marker levels in the PTC and reference group, which consists of all benign conditions. Width of the object
is proportional to the number of patients with a particular serum concentration.
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http://www.journalotohns.com/content/42/1/16tumor progression, apoptosis and metastasis and has been
detected in many human tumors and cell lines, including
thyroid, colon and breast. It has been identified in a number
of different tumors, and Xu et al. reported that it is
expressed preferentially in papillary and follicular carcinoma
at a high level and in medullary carcinoma at a variable level
[30]. Bartolazzi et al. used monoclonal antibodies to Gal-3
on 1009 archival tissues and 226 fresh specimens and
reported 99% sensitivity and 98% specificity in discriminat-
ing benign from malignant lesions [31]. However, a recent
study on PTC has observed that there was a decreased in-
tensity of Gal-3 expression at the invasive edges of the
tumors during tumor progression [32]. In 2010 Htwe et al.
showed a significant (p = 0.001) stronger expression of Gal-3
in the advancing follicular cells at the periphery of thyroid
cancer lesions, which was more pronounced in PTC than
follicular carcinoma of the thyroid [33]. In our study the
mean value of Gal-3 in PTC and control samples were 7.07
and 6.6 ng/ml, respectively, and the p-value was 0.48. These
results are consistent with those of Saussez et al. who
observed elevated Gal-3 levels in patients with PTC but
found significant overlap with Gal-3 levels in patients with
benign conditions [11].Cytokeratin 19 (CK19)
Cytokeratins are filamentous proteins that participate
in the integrity and cytoskeleton of the cells. CK19
has the lowest molecular weight of all the cytokera-
tins. It is normally expressed in ductal epithelium
(bile ducts, pancreas, and renal collecting tubules)
and in the mucosa of the gastrointestinal tract. The
differential expression of cytokeratins has been eval-
uated in various thyroid lesions. Among various
cytokeratins, CK19 has shown diffuse and strong
cytoplasmic staining in PTC, which makes it useful
in the diagnosis of PTC [34-39]. High molecular
weight cytokeratin has also been found to be signifi-
cantly increased in PTC and has been reported to be
helpful in distinguishing it from other benign and
malignant thyroid nodules [37,40]. In 2007, Park
et al. had showed that CK19 immunoreactivity of
follicular adenoma was higher than previously
reported cases, and because of its low specificity this
may limit its utility as a diagnostic marker [41]. Our
serum protein measurement didn’t show any signifi-
cant difference between PTC and benign thyroid
pathology.
Figure 3 Boxplot of the margin of prediction (positive values indicate correct classification). Multi-dimensional scaling plot of the random
forest proximity measure.
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Angiopoietins (Ang1 and Ang2) are structurally related
growth factors, and contribute to angiogenesis upon bin-
ding to Tie2 receptor [42]. Ang1 is known as a Tie2 agonist
capable of inducing EC migration and proliferation [43-46].
Interaction of angiopoietins with vascular endothelial
growth factors (VEGF) in different kinds of tumor tissue is
important for tumor growth and possible local invasion or
distant metastasis [47-49]. In 2006, Niedźwiceki et al. mea-
sured serum levels of Ang-1 using ELISA and showed
statistically significant lower concentrations of Ang-1 in
patients with thyroid cancers versus patients without
thyroid pathology [7]. In contrast, in 2011, Hsueh et al.
demonstrated the expression of Ang-1, Ang-2, and Tie-2 in
normal benign and PTC tissues and significantly high
expression of Ang-1 in metastatic PTC cases [50]. Based on
their results they also concluded that Ang-1, Ang-2, Tei-2
receptor, and VEGF play important roles in progression of
clinical stages of PTC [50]. Our measurements were con-
sistent with those of Niedźwiceki et al. [7] levels of Ang-1
were lower in PTC compared to normal. However, there
was no difference between serum Ang-1 levels in PTC and
the benign nodule group.
Despite significant evidence in the literature for eleva-
tion of these markers in tumor tissue, the same is not
true for serum. Underlying theories why serum values ofthese markers were not consistent with the tissue
values are unknown at this stage. In tumor tissue,
the availability of adjacent normal tissue facilitates
identification of markers. No such internal control is
possible for serum analysis; therefore, in the case of
serum markers, there must be a very large difference
in concentration in order for the marker to be useful
for diagnostic purposes.Conclusion
Although the results of this study did not demonstrate a
statistically significant difference in serum levels of YKL-40,
Gal-3, CK19, TIMP-1 and Ang-1 between PTC patients
and those with benign conditions, it does demonstrate the
potential feasibility of a blood-based diagnostic test. It also
demonstrates that although there may be up-regulation of
several of these gene products in PTC tissue, this
may not be representative of overexpression of the
proteins in serum.
With the rising incidence of thyroid cancer the
need for an accurate diagnostic test is becoming
paramount and development of such a test may sig-
nificantly reduce patient morbidity and unnecessary
surgery in benign thyroid disease. Obviously further
study is required.
Makki et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:16 Page 9 of 10
http://www.journalotohns.com/content/42/1/16Competing interests
The authors declare that they have no competing interests.Authors’ contributions
FM, AS, & KI: Ethics approval, patient enrollment, blood and tissue collection
and serum extraction. SD selected candidates for ELISA and assays were
performed by JG at the National Research Council. SMT & JT: staff head &
neck surgeons. MB: pathologist. DP, AL, & TE: data acquisition and tracking.
All authors read and approved the final manuscript.
Author details
1Department of Surgery, Division of Otolaryngology, Queen Elizabeth II
Health Sciences Centre and Dalhousie University, 1278 Tower Rd., Halifax, N.
S. B3H 2Y9, Canada. 2Department of Pathology, Queen Elizabeth II Health
Sciences Centre and Dalhousie University, 5788 University Ave., Halifax, N. S.
B3H 1V8, Canada. 3National Research Council of Canada, Institute for Marine
Biosciences, 1411 Oxford St., Halifax, N. S. B3H 4H7, Canada. 4QE II Health
Sciences Centre, 5788 Tower Rd., Halifax, N. S. B3H 2Y9, Canada.
Received: 15 November 2012 Accepted: 6 January 2013
Published: 7 February 2013References
1. Chappell H, Pritwish D, Dryer D, Ellison L, Logan H, MacIntyre M, et al:
Canadian cancer Society’s steering committee on cancer statistics. Toronto,
ON: Canadian Cancer Society; 2011.
2. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, et
al: Nonradiation risk factors for thyroid cancer in the US radiologic
technologists study. Am J Epidemiol 2010, 171(2):242–252.
3. Wiseman S, Baliski C, Irvine R, Anderson D, Wilkins G, Filipenko D, et al:
Hemithyroidectomy: the optimal initial surgical approach for individuals
undergoing surgery for a cytological diagnosis of follicular neoplasm.
Ann Surg Oncol 2006, 13(3):425–432.
4. Griffith OL, Melck A, Jones SJM, Wiseman SM: Meta-analysis and meta-
review of thyroid cancer gene expression profiling studies identifies
important diagnostic biomarkers. J Clin Oncol 2006, 24(31):5043–5051.
5. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska
M, et al: Gene expression profile of papillary thyroid cancer: sources of
variability and diagnostic implications. Cancer Res 2005, 65(4):1587–1597.
6. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, et al:
Gene profiling reveals specific oncogenic mechanisms and signaling
pathways in oncocytic and papillary thyroid carcinoma. Oncogene 2005,
24(25):4155–4161.
7. Niedzwiecki S, Stepien T, Kopec K, Kuzdak K, Komorowski J, Krupinski R, et al:
Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor
tyrosine kinase) concentrations in peripheral blood of patients with
thyroid cancers. Cytokine 2006, 36(36):291–295.
8. Lin SY, Wang YY, Sheu WH-H: Preoperative plasma concentrations of
vascular endothelial growth factor and matrix metalloproteinase 9 are
associated with stage progression in papillary thyroid cancer. Clin
Endocrinol 2003, 58(4):513–518.
9. Kashat L, So AK-C, Masui O, Wang XS, Cao J, Meng X, et al: Secretome-
based identification and characterization of potential biomarkers in
thyroid cancer. J Proteome Res 2010, 9(11):5757–5769.
10. Johansen JS, Lottenburger T, Nielsen HJ, Jensen JEB, Svendsen MN, Kollerup
G, et al: Diurnal, weekly, and long-time variation in serum concentrations
of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008,
17(10):2603–2608.
11. Saussez SGD, Chantrain G, Pattou F, Carnaille B, André S, Gabius HJ, Laurent
G: Serum galectin-1 and galectin-3 levels in benign and malignant
nodular thyroid disease. Thyroid 2008, 18(7):705–712.
12. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, et al:
Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary
liver cancer. Br J Cancer 2003, 88(12):1894–1899.
13. Lukasz A, Hellpap J, Horn R, Kielstein J, David S, Haller H, et al: Circulating
angiopoietin-1 and angiopoietin-2 in critically ill patients: development
and clinical application of two new immunoassays. Critical Care 2008,
12(4):R94.14. Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A, et al: Circulating
matrix metalloproteinases and their inhibitors in premature coronary
atherosclerosis. Clin Chem Lab Med 2001, 39(5):380–384.
15. Breiman L: Random forests. Machine Learning: Springer Netherlands;
2001:5–32.
16. Kundel AZR, Kato M, Moo TA, Zhu B, Scognamiglio T, Fahey TJ 3rd:
Comparison of microarray analysis of fine needle aspirates and tissue
specimen in thyroid nodule diagnosis. Diagn Mol Pathol 2010,
19(1):9–14.
17. Gharib H, Goellner JR: Fine-needle aspiration biopsy of the thyroid: an
appraisal. Ann Intern Med 1993, 118(4):282–289.
18. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, et al:
Gene expression in papillary thyroid carcinoma reveals highly consistent
profiles. Proc Natl Acad Sci USA 2001, 98(26):15044–15049.
19. Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, et al:
BRAFV600E mutation, TIMP-1 up-regulation and NF-KB activation:
closing the loop on the papillary thyroid cancer trilogy. Endocr Relat
Cancer 2011, 18(6):669–685. doi:10.1530/ERC-11-0076.
20. Maeta H, Ohgi S, Terada T: Protein expression of matrix metalloproteinases
2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary
thyroid carcinomas. Virchows Archiv 2001, 438(2):121–128.
21. Korem S, Resnick MB, Kraiem Z: Similar and divergent patterns in the
regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of
MMP-1 gene expression in benign and malignant human thyroid cells.
J Clin Endocrinol Metab 1999, 84(9):3322–3327.
22. Shi Y, Parhar RS, Zou M, Hammami MM, Akhtar M, Lum Z-P, et al: Tissue
inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced
stages of thyroid carcinoma. Br J Cancer 1999, 79(7-8):1234–1239.
23. Kraiem ZKS: Matrix metalloproteinases and the thyroid. Thyroid 2000,
10:1061–1069.
24. Komorowski JPZ, Jankiewicz-Wika J, Stepien H: Matrix metalloproteinases,
tissue inhibitors of matrix metalloproteinases and angiogenic cytokines
in peripheral blood of patients with thyroid cancer. Thyroid 2000,
12:655–662.
25. Patel A, Straight A, Mann H, Duffy E, Fenton C, Dinauer C, et al: Matrix
metalloproteinase (MMP) expression by differentiated thyroid carcinoma
of children and adolescents. J Endocrinol Invest 2002, 25(5):403–408.
26. Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, et al: Protein
alterations associated with pancreatic cancer and chronic pancreatitis
found in human plasma using global quantitative proteomics profiling.
J. Proteome Res 2011, 10(5):2359–2376.
27. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, et al:
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus
tamoxifen in metastatic breast cancer. J Clin Oncol 2008,
26(16):2653–2658.
28. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, et al: YKL-40, a
secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009,
28(50):4456–4468.
29. Coffman FD: Chitinase 3-Like-1 (CHI3L1): A putative disease marker at the
interface of proteomics and glycomics. Crit Rev Clin Lab Sci 2008,
45(6):531–562. doi:10.1080/10408360802334743.
30. Xu XC N-NA, Lotan R: Differential expression of galectin 1 and galectin-3
in thyroid tumors: potential diagnostic implications. Am J Pathol 1995,
147(3):815–822.
31. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al:
Application of an immunodiagnostic method for improving preoperative
diagnosis of nodular thyroid lesions. The Lancet 2001,
357(9269):1644–1650.
32. Türköz HK OH, Yurdakul Z, Ozcan D: Galectin-3 expression in tumor
progression and metastasis of papillary thyroid carcinoma. Endocr Pathol
2008, 19(2):92–96.
33. Htwe TTKN, Wong J, Jahanfar S, Mansur MA: Differential expression
of galectin-3 in advancing thyroid cancer cells: a clue toward
understanding tumour progression and metastasis. Singapore Med
J 2010, 51(11):856–859.
34. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle A, Kloos
RT: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19
immunohistochemistry is useful for the differential diagnosis of
thyroid tumors. Mod Pathol 2005, 18(1):48–57.
Makki et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:16 Page 10 of 10
http://www.journalotohns.com/content/42/1/1635. De Matos PS, Ferreira AP, De Oliveira Facuri F, AssumpÃ§Ã£o LVM,
Metze K, Ward LS: Usefulness of HBME-1, cytokeratin 19 and
galectin-3 immunostaining in the diagnosis of thyroid malignancy.
Histopathol 2005, 47(4):391–401.
36. Park MIKD: Usefulness of galectin-3, cytokeratin 19, p53, and Ki-67 for the
differential diagnosis of thyroid tumors. Korean J Pathol 2006, 40:86–92.
37. Raphael S, McKeown-Eyssen G, Asa S: High-molecular-weight
cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Mod Pathol 1994, 7(3):295–300.
38. Miettinen M, Kovatich AJ, Karkkainen P: Keratin subsets in papillary and
follicular thyroid lesions. Virchows Archiv 1997, 431(6):407–413.
39. Sahoo S, Hoda SA, Rosai J, DeLellis RA: Cytokeratin 19 immunoreactivity in
the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 2001,
116(5):696–702.
40. de Araujo VC, de Sousa SO, Carvalho YR, de Araujo NS: Application of
immunohistochemistry to the diagnosis of salivary gland tumors.
Appl Immunohistochem Mol Morphol 2000, 8(3):195–202.
41. Park YJ KS, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY,
Park SY: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high
molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential
diagnosis of thyroid nodules. Korean Medical Sciences 2007, 22(4):621–628.
42. Asahara DCT, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos
GD, Isner JM: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2,
modulate VEGF-induced postnatal neovascularization. Circ Res 1998,
83:233–240.
43. TI Koblizek CW, Yancopoulos GD, Deutsch U, Risau W: Angiopoietin-1
induces sprouting angiogenesis in vitro. Curr Biology 1998, 8:529–532.
44. Kanda S, Miyata Y, Mochizuki Y, Matsuyama T, Kanetake H: Angiopoietin 1
is mitogenic for cultured endothelial cells. Cancer Res 2005,
65(15):6820–6827.
45. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al:
Leakage-resistant blood vessels in mice transgenically overexpressing
angiopoietin-1. Science 1999, 286(5449):2511–2514.
46. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM:
Chemotactic Properties of angiopoietin-1 and -2, ligands for the
endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998,
273(29):18514–18521.
47. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al: Serum
angiopoietin-2 as a clinical marker for lung cancer. Chest 2007,
132(1):200–206.
48. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, et al:
Tetraiodothyroacetic acid (Tetrac) and nanoparticulate Tetrac arrest
growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab
2010, 95(4):1972–1980.
49. Wray CJ, Rilo HL, Ahmad SA: Colon cancer angiogenesis and
antiangiogenic therapy. Expert Op Invest Drugs 2004, 13(6):631–641.
50. Hsueh C, Lin J-D, Wu I-C, Chao T-C, Yu J-S, Liou M-J, et al: Vascular
endothelial growth factors and angiopoietins in presentations and
prognosis of papillary thyroid carcinoma. J Surg Oncol 2011,
103(5):395–399.
doi:10.1186/1916-0216-42-16
Cite this article as: Makki et al.: Serum biomarkers of papillary thyroid
cancer. Journal of Otolaryngology - Head and Neck Surgery 2013 42:16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
